% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • carcorpgm carcorpgm Jan 3, 2013 6:56 PM Flag

    Maybe Iplex isn't dead

    Biogen Idec's (Nasdaq: BIIB) potential treatment for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, has failed in a late-stage clinical trial, disappointing the company, patients and doctors. In a best-case scenario, that Phase 3 trial would have formed the basis of an application for U.S. Food and Drug Administration (FDA) approval.

    Weston, Mass.-based Biogen’s stock slid more than 3 percent Thursday morning, to $144.79, from a previous close of $150, after the company announced the news.

    The failure of the 900-patient Empower trial was so complete that the company will abandon development of the drug candidate, called dexpramipexole, or Dex.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
24.05-0.26(-1.07%)Sep 4 4:00 PMEDT